دورية أكاديمية
أعرض في EDS

Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity.

التفاصيل البيبلوغرافية
العنوان: Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity.
المؤلفون: Puranik AD; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Rangarajan V; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shetty NS; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Gala K; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Kulkarni S; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Mohite A; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Marotkar M; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Gawale Y; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Dev ID; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shrikhande SV; Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Chaudhari V; Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Bhandare M; Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Agrawal A; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shah S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Purandare NC; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Ghosh S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Choudhury S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
المصدر: Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India [Indian J Nucl Med] 2024 Mar-Apr; Vol. 39 (2), pp. 71-76. Date of Electronic Publication: 2024 May 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Country of Publication: India NLM ID: 8901274 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0972-3919 (Print) Linking ISSN: 09740244 NLM ISO Abbreviation: Indian J Nucl Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2008 : Mumbai : Medknow
Original Publication: [Delhi] : Society of Nuclear Medicine, India
مستخلص: Purpose: We proposed to administer Lu-177-DOTATATE in intra-arterial (IA) mode for higher first-pass localization to somatostatin receptors, higher residence time in liver metastases, and more radiation to tumor. This study aimed at assessing early hematological, renal and hepatotoxicity; and objective response to IA peptide receptor radionuclide therapy (PRRT).
Materials and Methods: Fourteen patients (4 females and 10 males) were prospectively assessed. 5/14 patients underwent 2 cycles, whereas 3/14 underwent 3 cycles, and 6/14 received 1 cycle of IA PRRT. 200 mCi of Lu-177-DOTATATE was administered in 15-20 min by IA route under angiographic guidance. Patients were asked to follow-up at 4 and 8 weeks with hematological, liver, and renal functional parameters, and Ga-68 DOTATATE positron emission tomography/computed tomography (PET/CT) after 8 weeks. Response was assessed using RECIST 1.1 and EORTC PET criteria.
Results: Safety: 2/14 patients had high total and direct bilirubin, which reverted to normal after IA PRRT. Three patients had low albumin, which improved after 1 cycle. Nine patients showed no worsening of liver function. Two patients showed Grade 1 hematotoxicity which reverted to normal. Five patients showed high creatinine, but preserved glomerular filtration rate and EC clearance. On follow-up at 8 weeks, serum creatinine reverted to normal. Efficacy: In five patients who underwent 2 cycles of IA PRRT, 3 showed partial response (PR) on RECIST 1.1 and partial metabolic response (PMR) on EORTC criteria, whereas 2 showed stable disease (SD). In patients who underwent 3 cycles, 1 showed SD, whereas other patient showed PMR on DOTANOC PET/CT, with PR in size. Among the remaining seven patients, 5 showed PMR, whereas the other 2 showed SD. Thus 9/14 patients showed PR, whereas 5 showed SD on metabolic and size criteria.
Conclusions: IA PRRT is a safe and efficacious approach for the treatment of liver dominant metastatic neuroendocrine tumors.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2024 Indian Journal of Nuclear Medicine.)
References: Br J Radiol. 2021 Oct 01;94(1126):20210403. (PMID: 34357794)
J Clin Oncol. 2008 May 1;26(13):2124-30. (PMID: 18445841)
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. (PMID: 32123969)
Q J Nucl Med Mol Imaging. 2012 Dec;56(6):551-8. (PMID: 23358409)
BMC Cancer. 2019 Aug 8;19(1):788. (PMID: 31395036)
Pancreas. 2014 May;43(4):518-25. (PMID: 24632546)
Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33. (PMID: 24504504)
Endocr Relat Cancer. 2011 Sep 20;18(5):595-602. (PMID: 21791571)
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. (PMID: 28428192)
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46. (PMID: 25808630)
Trials. 2020 Feb 5;21(1):141. (PMID: 32024533)
J Nucl Med. 2014 Feb;55(2):183-90. (PMID: 24434296)
Cancer Biother Radiopharm. 2014 May;29(4):179-87. (PMID: 24820805)
N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709)
Lancet Oncol. 2014 Jan;15(1):e8-21. (PMID: 24384494)
Int J Cardiol. 2017 Feb 1;228:137-144. (PMID: 27863354)
فهرسة مساهمة: Keywords: Intra-arterial; liver metastases; neuroendocrine; peptide receptor radionuclide therapy
تواريخ الأحداث: Date Created: 20240711 Latest Revision: 20240712
رمز التحديث: 20240712
مُعرف محوري في PubMed: PMC11232720
DOI: 10.4103/ijnm.ijnm_7_23
PMID: 38989301
قاعدة البيانات: MEDLINE
الوصف
تدمد:0972-3919
DOI:10.4103/ijnm.ijnm_7_23